PDS Biotechnology Corporation (PDSB)
| Market Cap | 362.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.57M |
| Shares Out | 23.16M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,136,886 |
| Open | 13.75 |
| Previous Close | 13.60 |
| Day's Range | 11.96 - 13.75 |
| 52-Week Range | 1.87 - 17.85 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 19.71 (+59.9%) |
| Est. Earnings Date | Nov 10, 2021 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is 19.71, which is an increase of 59.85% from the latest price.
News
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-1...
FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination ...
No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...
Best Penny Stocks To Buy In 2021? 5 That Turned $2,500 Into $26,000
Were these penny stocks on your list this year? The post Best Penny Stocks To Buy In 2021?
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fiduci...
PDS Biotechnology Joins Russell Microcap® Index
FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Und...
FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of...
PDS Biotech Announces Proposed Offering of Common Stock
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therap...
PDS Biotechnology Announces Oncology Research and Development Day
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company's...
Why PDSB Shares Are Trading Higher Today
PDS Biotechnology Corp (NASDAQ:PDSB) shares are trading higher by 13.3% at $10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical stu...
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Stu...
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advan...
PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients
PDS Biotechnology Corporation (NASDAQ: PDSB) has announced interim data from the Phase 2 trial led by the National Cancer Institute (NCI) evaluating PDS0101 (Versamune-HPV16) in combination with two inv...
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at A...
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advan...
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Pa...
FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...
PDS Biotech to Host Oncology R&D Day on June 16, 2021
FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance
Strategic partnership offers both organizations a way to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer Strategic partnershi...
Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options
Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting
FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprie...
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
NetScientific hails the potential of investee company's cancer immunotherapy
NetScientific PLC (LON:NSCI) said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy. PDS Biotechnology Corporation (NASDAQ:...